Thrombocytopenia

88

Pipeline Programs↗

40

Active Trials↗

45

Companies Involved↗

Thrombocytopenia is a moderately active landscape with 88 programs across 45 companies. The most active players are Ono Pharmaceutical Co. Ltd, Tarix Pharmaceuticals, Karyopharm Therapeutics Inc. 20 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

41/100

Mech. Concentration

14/100

Completion Rate

61/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Ono Pharmaceutical Co. Ltd

1 program

Tarix Pharmaceuticals

1 program

Karyopharm Therapeutics Inc

1 program

Veralox Therapeutics

1 program

Merck & Co.

1 program

UCB

1 program

Analysis

Modality Breakdown

89%

Small molecule

85 of 96 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 96 classified programs, each share of the total. Modality classified for 100% of 106 pipeline programs.

Analysis

Trial Status

154

clinical trials

Completed50 · 32%

Unknown status31 · 20%

Terminated23 · 15%

Recruiting22 · 14%

Not yet recruiting14 · 9%

Withdrawn9 · 6%

Other5 · 3%

Clinical Trials

Trial Activity

154 trials

Herombopag for Chemotherapy-induced Thrombocytopenia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05236582·50 enrolled

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04600960·50 enrolled

Apixaban in Thrombocytopenia

Recruiting·—·Phase 1·NCT06886516·30 enrolled

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Recruiting·—·Phase 2·NCT07492693·40 enrolled

Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

Recruiting·—·Phase 4·NCT06562738·55 enrolled

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Recruiting·PPeking University People's Hospital·Phase 2/3·NCT06202625·142 enrolled

Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia

Recruiting·—·N/A·NCT06033300·200 enrolled

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06507436·101 enrolled

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT05980806·58 enrolled

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06433830·50 enrolled

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 2·NCT05394285·60 enrolled

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT04800458·225 enrolled

Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

Recruiting·—·Phase 1·NCT07110090·16 enrolled

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2/3·NCT06456528·235 enrolled

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

Recruiting·FFudan University·Phase 2·NCT05442632·96 enrolled

Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)